Message from the Management Team

At PharmaEssentia, we uphold our founding mission by proactively investing in development of new drugs to meet patient needs. We work closely with our business partners to ensure the quality and safety of our drugs. Thanks to continued growth of Ropeginterferon alfa-2b (Ropeg) sales in the US and global markets, our revenue for 2025 rose significantly, and consolidated Group revenue reached NT$15.634 billion, increasing by 60.61% compared to 2024. Our operating profit reached NT$4.928 billion, net profit reached NT$5.045 billion, and our EPS was NT$13.64. Our operating profit, net profit, and EPS once again reached record heights.

In 2025, we actively improved upon our environmental, social, and governance sustainability performance, consolidating our role as a sustainability benchmark in the biotechnology and pharmaceuticals industry.

Environment (E): We conducted greenhouse gas inventories at PharmaEssentia’s Taipei Office and Taichung Plant, and obtained ISO 14064-1 verification. We continue to implement an energy management system at our Taichung Plant to enhance our energy efficiency, with the main measures being: (1) Establishing a refrigerant reclamation system to reduce compressor load and energy consumption, enable electricity savings, and lower carbon emissions; (2) Optimizing chiller flow by adding variable frequency drives to pump systems to reduce energy consumption; (3) Establishing an energy information dashboard and database to monitor, manage, and analyze energy usage. We have issued a Biodiversity and No Deforestation Commitment, and will continue to focus on environmental issues in future as we make progress toward our sustainability commitments.

Social (S): PharmaEssentia promotes access to medicine. A total of 59 patients benefited from our compassionate treatment program in 2025. We operate patient support programs in Taiwan, Japan, and the US, and also participate in international myeloproliferative neoplasms (MPN) academic exchange activities and local community MPN empowerment activities to enhance physician and patient understanding of MPN. In 2025, we continued to work with the Digital Humanitarian Association on remote health promotion projects in rural areas to provide health care for older adults in Taiwanese communities. We plan to continue contributing to MPN care and community well-being through the health care and pharmaceuticals industries.

Governance (G): PharmaEssentia continues to implement management of intellectual property rights and trademarks. We designed courses explaining how to operate our intellectual property rights management platform and launched a corporate identity mark redesign program in the fourth quarter of 2025. We also continue to enhance sustainable supply chain management. We initiated signing procedures for our Supplier Code of Conduct in 2025, and will establish on-site visits and audit report mechanisms to review supplier sustainability performance in future as we work with our value chain partners to achieve mutual sustainability benefits.

We plan to continue making progress on all sustainability performance and achievements in accordance with our Sustainable Development Roadmap as we work to become a sustainability benchmark in the biotechnology and pharmaceuticals industry.

PharmaEssentia is focused on the production of self-developed interferon and PEG products. Our independently developed new drug Ropeg (P1101) has been approved for polycythemia vera (PV) treatment in nearly 50 countries around the globe, and has been recommended as a first-line treatment for both high- and low-risk PV patients by the National Comprehensive Cancer Network (NCCN) for three consecutive years. We are working to expand Ropeg indications for essential thrombocythemia (ET) and primary myelofibrosis (PMF). In early 2026, Ropeg was recommended by the NCCN as a Category 1 “preferred regimen” treatment for high-risk ET patients with poor or ineffective responses to current treatments, and we are actively working with the U.S. Food and Drug Administration (FDA) and other competent authorities to complete relevant review processes. We hope to obtain marketing authorizations in various regions starting from 2026.

PharmaEssentia sees significant market potential for Ropeg and has continually expanded production capacity in recent years. We have completed construction on the external steel structure of our Hsinchu Zhubei Plant, and the plant is officially scheduled to commence operations in 2026 after the internal facilities and offices are completed. Our Taichung Houli Plant is also under construction, and we expect future capacity will meet medication demands for more than 100,000 patients globally. This plant will support our pursuit of new business opportunities after we obtain ET and PMF marketing authorizations. Additionally, we plan to invest US$12 million in the US to establish a manufacturing facility in Puerto Rico so we can move toward a “US-Taiwan dual production base” operational model that strengthens our supply chain resilience and lowers overall manufacturing costs while expanding our global production roadmap.

In 2025, PharmaEssentia continued to focus on sustainability issues encompassing cultivation of biotechnology talents, employee care, and social participation. In terms of talent cultivation and employee care, PharmaEssentia implemented a summer internship program which gathered students from universities around the globe and shared practical knowledge on “digital empowerment” and “cross-domain perspectives.” These cross-departmental internships helped interns develop the capabilities for proposing solutions to meet specific demands. In response to production line expansions, PharmaEssentia recruited and retained talent by continuing to promote employee stock purchase plans as a long-term employee incentive mechanism which allows employees to grow alongside the Company. In terms of social participation, PharmaEssentia continued to offer compassionate treatment by donating drugs to patients who required timely access to treatment. A total of 59 patients benefited from our compassionate treatment program in 2025. We also continued to sponsor local MPN patient groups and collaborate with medical teams and academic institutes to focus on MPN care and treatment issues that can benefit more patients around the world.

PharmaEssentia gained significant acclaim and recognition from domestic and foreign institutions in 2025. Our international sustainability Standard & Poor’s Corporate Sustainability Assessment (S&P CSA) performance for the previous year ranked in the 2025 S&P Global Sustainability Yearbook, and we received the Industry Mover award. Our S&P CSA score for 2025 ranked in the top 10% of the global biotechnology industry. In 2025, we also received the 1.5°C Climate Certification from CommonWealth Magazine, the Taiwan Corporate Sustainability Awards (TCSA) Gold Corporate Sustainability Report Award (Health Care Category 1), and the 22nd National Innovation Award Corporate Innovation Award. Looking to the future, PharmaEssentia will continue to balance sustainability performance with business expansions to achieve mutual wins for all stakeholders.